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Abstract. Similarly  to  Epstein-Barr  virus  (EBV),  the  human  herpesvirus
herpesvirus, recently recognized to be associated with the occurrence of rare B cell lymphomas and 
atypical  lymphoproliferations,  especially
subjects.  Moreover,  the  human  herpesvirus
implicated in some non-malignant lymph node proliferations, such as the Rosai Dorfman disease, 
and in a proportion of Hodgkin’s lymphoma cases. HHV
play a role in the pathogenesis of a wide variety of human diseases, but given its ubiquity, disease 
associations are difficult to prove and its role in hematological malignancie
The involvement of another β-herpesvirus, the human cytomegalovirus (HCMV), has not yet been 
proven  in  human  cancer,  even  though  recent  findings  have  suggested  its  potential  role  in  the 
development of CD4
+ large granular lymphocyt
knowledge  on  the  pathogenetic  role  of  HHV
lymphoproliferative disorders.
Introduction. Epstein-Barr  virus  (EBV)  is  a  γ
herpesvirus  well  recognized  to  be  involved  in  the 
development of human B and NK/T cell lymphomas, 
either  in  the  general  population  or  in  the 
immunosuppressed individuals. EBV is a lympho
epitheliotropic  γ-herpesvirus  apparently  carried  as  an 
harmless  passenger  in  the  immunocompetent  host. 
Alterations in  the delicate balance between the virus 
and the host immune control may result in a wide range 
of  EBV-associated  diseases:  the  simplest  scenario  is 
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Barr  virus  (EBV),  the  human  herpesvirus
herpesvirus, recently recognized to be associated with the occurrence of rare B cell lymphomas and 
atypical  lymphoproliferations,  especially in  the  human  immunodeficiency  virus  (HIV)  infected 
subjects.  Moreover,  the  human  herpesvirus-6  (HHV-6),  a  β-herpesvirus,  has  been  shown  to  be 
malignant lymph node proliferations, such as the Rosai Dorfman disease, 
n of Hodgkin’s lymphoma cases. HHV-6 has a wide cellular tropism and it might 
play a role in the pathogenesis of a wide variety of human diseases, but given its ubiquity, disease 
associations are difficult to prove and its role in hematological malignancie
herpesvirus, the human cytomegalovirus (HCMV), has not yet been 
proven  in  human  cancer,  even  though  recent  findings  have  suggested  its  potential  role  in  the 
large granular lymphocyte (LGL) lymphocytosis. Here, we review the current 
knowledge  on  the  pathogenetic  role  of  HHV-8  and  human  β-herpesviruses  in  human 
Barr  virus  (EBV)  is  a  γ-
herpesvirus  well  recognized  to  be  involved  in  the 
development of human B and NK/T cell lymphomas, 
either  in  the  general  population  or  in  the 
immunosuppressed individuals. EBV is a lympho- and 
herpesvirus  apparently  carried  as  an 
harmless  passenger  in  the  immunocompetent  host. 
Alterations in  the delicate balance between the virus 
and the host immune control may result in a wide range 
associated  diseases:  the  simplest  scenario  is 
the  outgrowth  of  EBV-transformed  B
expressing the full array of EBV latent gene (EBNA1, 
2, 3A, 3B, 3C, LP, LMP1 and LMP2) leading to the 
development  of  post-transplant  lymphoproliferative 
disease (PTLD) in immunodeficient subjects. EBV is 
also  associated  to  malignancies in  immunocompetent 
hosts  arising  from  either  epithelial,  T  cell  or  B  cell 
origin  in  which  is  present  with  a  limited  pattern  of 
latency  genes:  latency  II  (expression  of  EBNA1, 
LMP2A)  is  typical  of  Nasopharingeal  Carcinoma, 
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Barr  virus  (EBV),  the  human  herpesvirus-8  (HHV-8)  is  a  γ-
herpesvirus, recently recognized to be associated with the occurrence of rare B cell lymphomas and 
in  the  human  immunodeficiency  virus  (HIV)  infected 
herpesvirus,  has  been  shown  to  be 
malignant lymph node proliferations, such as the Rosai Dorfman disease, 
6 has a wide cellular tropism and it might 
play a role in the pathogenesis of a wide variety of human diseases, but given its ubiquity, disease 
associations are difficult to prove and its role in hematological malignancies is still controversial. 
herpesvirus, the human cytomegalovirus (HCMV), has not yet been 
proven  in  human  cancer,  even  though  recent  findings  have  suggested  its  potential  role  in  the 
e (LGL) lymphocytosis. Here, we review the current 
herpesviruses  in  human 
transformed  B-lymphoblasts, 
expressing the full array of EBV latent gene (EBNA1, 
2, 3A, 3B, 3C, LP, LMP1 and LMP2) leading to the 
transplant  lymphoproliferative 
disease (PTLD) in immunodeficient subjects. EBV is 
ted  to  malignancies in  immunocompetent 
hosts  arising  from  either  epithelial,  T  cell  or  B  cell 
origin  in  which  is  present  with  a  limited  pattern  of 
latency  genes:  latency  II  (expression  of  EBNA1, 
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Gastric Carcinoma and Hodgkin’s Lymphoma; latency 
I (expression of EBNA1) is associated to the Burkitt 
Lymphoma.
1
In addition to EBV, another γ-herpesvirus, Kaposi’s 
sarcoma-associated herpesvirus (KSHV or HHV-8) is 
oncogenic.  Among  β-herpesviruses,  several 
investigators have suggested that human herpesvirus-6 
(HHV-6)  also  may  be  an  oncogenic  virus.  Here, we 
review the current knowledge on the pathogenetic role 
of  human  β-herpesviruses  and  HHV-8  in  human 
lymphoproliferative disorders.
 HERPESVIRUSES: 
HHV-6. Epidemiology and biology. HHV-6 was first 
isolated in 1986 and later two viral variants have been 
identified, namely HHV-6A and HHV-6B, showing an 
overall nucleotide sequence identity of 90%. HHV-6 is 
ubiquitous  in  human  throughout  the  world,  with 
seroconversion  occurring  early  in  life.
2,3 Salivary 
contact is likely to be the vehicle for transmission, but 
intrauterine  passage  is  also  possible.  HHV-6  can  be 
transmitted by blood products and with bone marrow 
and  solid  organ  transplantation.  Through  its  cellular 
receptor  CD46, an  ubiquitary  complement  regulatory 
glycoprotein
4, HHV-6 can primarily infect either early 
self-renewing bone marrow precursors or mature blood 
cells, as well as oropharinx/salivary glands, epithelial 
mucosa  of  female  genital  tract  and  brain  tissue. 
Following  primary  infection,  HHV-6  can  persist 
lifelong  mainly  in  monocytes  and  other  peripheral 
blood  mononuclear  cells.
3 Only  rare  cells  remain 
latently infected  in  healthy individuals,  as shown  by 
PCR  testing.  Of  note,  HHV6,  unique  among  all  the 
herpesviruses, exhibits a particular form of persistence 
in the infected cell, consisting in the integration of the 
whole  viral  genome  into  host  chromosomes.  The 
prevalence of the ‘chromosomal integration of HHV-6’ 
(CIHHV-6) ranges from 0.2% to 3% among different 
geographical  areas.
5,6 It  has  been  observed  that  the 
main route of acquisition of CIHHV-6 is the vertical 
transmission, which implies that at least one copy of 
viral DNA is present in all the nucleated cells of the 
host. The HHV-6 genome shows human telomere-like 
repeat sequences at both its ends and this may foster 
the  viral  integration  in  some  preferred  chromosomal 
regions  (mainly  17p13.3,  22q13,  1q44),  which  are 
close to or within the telomeres.
7-10
HHV-6  has  been  demonstrated  to  efficiently 
replicate in vitro and cause a cytopathic effect either in 
CD4+  T  lymphocytes  or  in  thymocytes,  inducing  a 
suppression of T-cell functions. Cells transfected with 
HHV-6 can cause tumors in nude mice.
11 However, the 
evidence  linking  HHV-6  to  human  hematological 
malignancies  is  circumstantial,  and  far  from 
definitive.
12  HHV-6  DNA  can  transform  human 
epidermal keratinocytes and NIH 3T3 cells in vitro.
13-14
HHV-6 has a number of unique genes that are plausible 
causes  of  oncogenesis.  Its  ORF-1  gene  encodes  a
protein that is capable of transforming NIH 3T3 cells in 
vitro,  and  cells  expressing  ORF-1  protein  produce 
fibrosarcomas  when  injected  into  nude  mice.
15 The 
ORF-1  protein appears  to  maintain  the  transformed 
state  of  tumor  cells  by  binding  p53  and  thereby 
inhibiting  its  tumor  suppressor  properties.
16 HHV-6 
also has a unique immediate early gene called U95 that 
has binding sites for nuclear factor-kappa B (NF-kB).
17
Dysregulation  of  NF-kB  has  been  postulated  to 
contribute  to  cancer,  through  its  effects  on  both  the 
proliferative and apoptotic pathways.
18 (Table 1)
Hodgkin’s  disease. Reports  differ  as  to  the  possible 
role of HHV-6 in Hodgkin’s disease (HD). Torelli et 
al.
19 reported finding HHV-6 sequences by PCR in 3 of 
25 cases of HD, all nodular sclerosis type, and in none 
of 41 cases of non-Hodgkin’s lymphoma. Krueger et 
al.
20 performed immunohistochemical studies of tumors 
from 103 patients with HD, and found tissue sections 
to  be  infected  frequently  by  both  EBV  and  HHV-6; 
lymphocytes  and  histiocytes  were  infected 
preferentially.  Lacroix  et  al.
21 found  HHV-6  DNA 
more frequently in the nodular sclerosis form of HD: of 
73 patients with nodular sclerosis, 39 (49%) had both 
HHV-6 and EBV DNA, 25 (34%) had only HHV-6, 
and 8 (11%) had only EBV. In contrast, of 10 cases of 
the mixed cellularity form of HD, 4 (40%) had both 
viruses, 1 had HHV-6 only, 4 had EBV only, and 1 had 
neither. HHV-6
+/EBV
- patients were younger than the 
EBV
+/HHV-6
- patients and 92% of the HHV-6
+ lymph 
nodes  contained  variant  B.  However,  Luppi  et  al.
22
examined a large series of patients with HD in which 
HHV-6 DNA was found by both  PCR and Southern 
blot analysis, did not detect either latent or lytic HHV-
6 antigens in neoplastic cells, and detected only limited 
expression in Reed–Sternberg cells. Thus, the role of 
HHV-6 in any form of HD remains unclear. Recently, 
Lacroix  et  al.
23 showed  the  transforming, 
transactivating  and  oncogenic  properties  of  HHV-6B 
and localized the transforming activity into DR7 gene. 
Cells  expressing  viral  DR7  protein  revealed 
tumorigenic properties when injected into nude mice. 
The  expression  of  DR7B  protein  in  Reed-Sternberg 
cells  from  HD  patients  causes  molecular  alterations 
into  the  cells  typical  of  the  lymphoproliferative 
disorder.  In  particular,  the  oncoprotein  protects 
infected cells from apoptosis by retaining human p53 
within the cytoplasm and by increasing NF-kB cellular 
transcription  factor.  The  action  on  NF-kB  is  mainly 
exerted through two mechanisms: the transactivation of 
the expression of its subunities p65 and p50-p105 and 
the  direct  interaction  of  DR7B  with  the  assembled Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
protein. Lastly, DR7B promotes the overexpression of 
Id2,  inhibitor  of  E2A  transcription  factor,  that 
negatively  regulates  cell  differentiation.
23 Further 
studies are needed to confirm a plausible pathogenetic 
role of HHV-6 infection in HD. 
Non-Hodgkin’s  lymphomas. Luppi  et  al.
24 reported  a 
higher  frequency  of  HHV-6  DNA  in  a  well-
characterized  series  of  patients  with 
angioimmunoblastic  T-cell  lymphoma  (AITL),  a 
subtype  of  T-cell  non-Hodgkin’s  lymphoma  (NHL), 
compared with other lymphoma subtypes and controls. 
These findings have been confirmed by Zhou et al.
25
showing  a  clear  association  between  histological 
progression of AITL and the detectable copy number 
of both EBV and HHV-6B in the AITL lesional tissue. 
While this increased viral load could reflect a role for 
HHV-6 in the pathogenesis and progression of AITL, it 
could  also  be  the  consequence  of  increasing 
dysfunction of the immune system during lymphoma 
progression. Immunohistochemical studies have so far 
failed to demonstrate HHV-6 antigens in the CD4+ T 
cells  (the  likely  proliferating  elements)  within  AITL 
lesions.
Leukemias. Persistent IL-2-regulated HHV-6 infection 
of adult T-cell leukemia cells causes T-cell leukemia to 
progress more rapidly,
26 but in vivo studies have not 
yet confirmed a pathogenetic role for HHV-6 in this 
disease.  Few  other  studies  aiming  to  investigate  the 
association of HHV-6 with acute leukemia have been 
reported. The largest study showed significant higher 
titres of HHV-6  antibodies  in  patients  with acute 
myeloid  leukemia,  but  not  with  acute  lymphoblastic
leukemia.
27 Salonen et al.
28 found that 40% of children 
with leukemia had IgM antibodies to HHV-6 compared 
to 7.7% of age- and sex-matched children with various 
neurological  diseases.  However,  molecular  studies 
have so far failed to show a higher rate of HHV-6 DNA 
in  peripheral  blasts  from  children  with  acute 
lymphoblastic  leukemia  compared  with  healthy 
subjects.
29 A  recent  report  found  higher  rates  of 
seropositivity  to  human  cytomegalovirus  (HCMV) 
among  patients  with  B-cell  chronic  lymphocytic 
leukemia  than  among  healthy  control  subjects, 
although  restricted  only  to  some geographical  areas, 
but the same was not true for seropositivity to HHV-6 
(or  EBV  and  HHV-7).
30 In  conclusion,  with  the 
possible exception of adult T-cell leukemia, available 
data do not lend support to a role for HHV-6 in human 
acute leukemias.
Non-malignant  lymphatic  tissue  proliferation. Of 
interest, HHV-6 late antigens have so far been detected 
only  in  non-malignant  lymph  node  proliferations, 
namely in cases of reactive lymphadenitis,
31, 32 in which 
HHV-6  antigens  appear  to  be  restricted  to  CD4+T 
cells. HHV-6 late antigens have also been identified in 
cases of Rosai Dorfman disease, otherwise known as 
sinus  histiocytosis  with  massive  lymphadenopathy,  a 
benign chronic disease, mainly affecting children and 
young adults  and with  no progression  to  lymphoma. 
HHV-6 infection appears to be restricted to follicular 
dendritic cells and, more significantly, to the abnormal 
histiocytes that represent the proliferating elements and 
the hallmark of this disease.
33 (Table 1)
HCMV.  Epidemiology  and  biology. HCMV  was 
simultaneously isolated from salivary glands by Rowe 
and  Smith  in  1956.  This  virus  was  designated 
‘cytomegalovirus’ and the associated clinical syndrome 
was referred to as ‘cytomegalovirus inclusion disease’ 
because viral cytopathic effects typically result in cell 
swelling and intranuclear inclusions.
HCMV infection is widespread in the entire human 
population,  with  prevalence  increasing  with  age.  In 
Western Countries, seropositivity rates range 40-70%, 
while in developing countries are much higher.
34 Using 
PCR, CMV viremia has been detected in about 98% of 
healthy individuals over 50 years of age. HCMV can 
be  transmitted  orally,  sexually,  and  parenterally; 
primary  infection  may  be  subclinical  in  healthy 
subjects.  Even  asymptomatic  carriers  may  at  times 
shed HCMV in urine and saliva.
35-36
HCMV  productive  infection  (lytic  cycle)  is 
restricted to endothelial cells and fibroblasts, typically 
causing  cell  death  and  tissue  damage  in  lung,  liver, 
colon,  brain  and  retina.  Similarly  to  other 
herpesviruses,  HCMV  can  establish  lifelong  latent 
infection  in  the  host,  mainly  in  macrophages  and 
hematopoietic  stem  cells/progenitors  (then  passively 
transmitted to the mature myeloid progenies), and is a 
recognized  cause of  mononucleosis-like  syndromes.
36
(Table 1)
Large granular lymphocyte proliferation. In contrast to 
HHV-6, HCMV has not been proven to be involved in 
human  cancer.  However,  Rodriguez-Caballero  and 
colleagues
37 suggested  a  role  of  HCMV  in  the 
pathogenesis  of  a  specific  subtype  of  large  granular 
lymphocyte (LGL) proliferation involving CD4
+/CD8
+/-
dim T  cells.  In  particular,  they  used  microarray  gene 
expression profile (GEP) to show that CD4
+ T cells in 
patients  with  CD4
+ LGL  expansions,  differ 
significantly  from  HCMV-specific  memory  CD4
+
lymphocytes derived from healthy control individuals. 
The chronic antigenic stimulation of T cells by HCMV 
can  lead  to  persistent  monoclonal  expansion  of 
vβ13.1/CD4
+ NKa
+ CD8dim
+ lymphocytes presenting a 
deregulation  of  genes  involved  in  cell  cycle Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
progression,  resistance  to  apoptosis  and  genetic 
instability.  The  observed  deregulation  of  key  genes 
allows these cells to accumulate in excess to what is 
required to control HCMV infection and to abnormally 
proliferate. (Table 1)
γ HERPESVIRUSES
HHV-8.  Epidemiology  and  biology. Human 
herpesvirus-8  (HHV-8)  was  identified  by  Moore  & 
Chang in 1994, from the Kaposi’s sarcoma (KS) tissues 
of patients with AIDS. HHV-8 is not ubiquitous in the 
general population: the infectious rates are low in the 
United Kingdom, United States and Asia, intermediate 
in Mediterranean countries and high in Central Africa. 
The  seroprevalence  of  HHV-8  among  blood  donors 
ranges from 0.2% in Japan, to up to 10% in the United 
States, and to more than 50% in Africa,
38 with rates in 
Italy and other Mediterranean countries falling between 
these  percentages.
39,40 HHV-8  is  mainly  spread  by 
sexual  route  in  non-endemic  areas,  while  non-sexual 
transmission may be important in endemic areas where 
infection is usually acquired early in the childhood. 
HHV-8  is  classified as a γ-herpesvirus, related to 
EBV  and  Herpesvirus  Saimiri.  Like  other 
herpesviruses, HHV-8 is a large, double-stranded DNA 
virus that replicates in the nucleus as a closer circular 
episome  during  latency,  but  linearizes  during  virion 
packaging  and  replication.  The  HHV-8  genome 
typically contains genes that are homologous to cellular 
genes  involved  in  the  control  of  cell  cycle  and 
apoptosis. Similarly to other herpesviruses, HHV-8 has 
evolved to persist within the lymphoid system and has 
shown  an  oncogenic  potential. HHV-8  infection  has 
been  described  in  association  with  rare 
lymphoproliferative  disorders,  including  primary 
effusion  lymphoma  (PEL),  multicentric  Castleman’s 
disease  (MCD),  and  MCD-associated  plasmablastic 
lymphoma, often occurring in AIDS patients. A subset 
of  viral  proteins  is  expressed  in  HHV-8-associated 
lymphoproliferative disorders and are involved in the 
viral lymphomagenesis. The viral proteins expressed in 
most  PEL  cells  are  the  following:  latency-associated 
nuclear  antigen  1  (LANA  -1),  v-Cyclin,  v-FLICE
inhibitory  protein  (v-FLIP), v-interferon  regulatory 
factor/LANA-2, Kaposin,  v-Interleukein-6  (v-IL-6). 
LANA-1,  v-Cyclin,  v-FLIP  and  v-IL-6  are  also 
expressed in most of the MCD cases. Two additional 
proteins, namely the K1 and the v-G-protein-coupled 
receptor (v-GPCR) are expressed in few cases of PEL 
and MCD.
41 (Table 1)
Primary Effusion Lymphoma. PEL has been included 
in the WHO classification as a distinct entity among 
AIDS-associated NHLs, representing about 3-4% of all 
AIDS-NHLs.
42-44 The lymphoma grows predominantly 
in serous effusions, without solid tumor masses in the 
affected body cavity,
45-47 while involvement of lymph 
nodes,
48 bone  marrow
49,50 or  other  tissues
51 is 
occasionally seen. A number of continuous cell lines 
has  been  established  from  such  lymphomatous 
effusions and peripheral blood of PEL patients.
52 The 
PEL  cells  can  include  features  of  large  cell 
immunoblastic  and  anaplastic  lymphoma,
53 and  also 
sometimes  express  a  more  plasmacytoid  cytology.
42
PEL  cells  generally  lack  immunophenotypical 
expression of differentiated B- or T- cell antigens, but 
for MUM1 and CD138, reflecting their post-germinal 
centre  B-cell  origin.  Consistent  with  this,  the  gene 
expression  profile  analysis  suggests  a  plasmablastic 
derivation  of  PEL  cells.
54,55 They  express  cell 
activation  associated  markers,  including  HLA-DR, 
CD23,  CD25,  CD30  and  CD38,  and  the  epithelial 
membrane  antigen  whereas  adhesion  markers  are 
variably expressed.
43,52 The B cell lineage derivation of 
PEL  cells  is  established  on  the  basis  of  clonal 
rearrangements  of  the  heavy  immunoglobulin  (Ig) 
genes,
45,52 and the PCR-based findings of a preferential 
expression  of  certain  lambda  light  chain  genes  in 
AIDS-related PELs, suggesting clonal proliferation by 
an antigen selection process.
56 A few cases of AIDS-
related  PEL  did  not  demonstrate  Ig  gene 
rearrangements, consistent with a polyclonal pattern of 
lymphoproliferation.
47 In  contrast  to  other  non 
Hodgkin’s B-cell lymphoma types, neither c-MYC nor 
other proto-oncogene rearrangements were detected in 
PELs.
54 Likewise, a wild type of the tumor suppressor 
p53 gene is expressed by PELs, while mutations of the 
BCL-6 5’ non-coding regions have been documented in 
most of the cases.
52 PELs show complex karyotypes, 
the  most  frequent  chromosomal  abnormalities  being 
trisomy 7, 12 and aberrations of chromosomal bands 
1q21-q25.
52 Virtually all reported cases of PEL have a 
relatively  high  number  of  HHV-8  DNA  copies  (40-
150)  per  cell,  most  cells  being  latently  infected  and 
relatively few permissive for lytic infection as obtained 
in  cultured  PEL  lines.  Analysis  of  HHV-8  terminal 
repeats  (TR)  by  pulsed-field  gel  electrophoresis  has 
shown monoclonal or oligoclonal fused TR fragments 
in  all  examined  cases  of  PEL,  suggesting  HHV-8 
infection  of clonogenic  cells, supporting an  etiologic 
role of the virus in these lymphoproliferations.
57 EBV 
co-infection  is  detected  in  many  cases  of  PEL,  also 
with  a  monoclonal  infection  pattern  and  with  a 
restricted antigen expression pattern of latency. Human 
interleukin-6  (IL-6)  and  -10  (IL-10),  v-IL-6  and 
vascular  endothelial  growth  factor  (VEGF)  are  the 
major growth factors released and used by PEL cells 
for autocrine growth stimulation.
52,58-60 The occurrence 
of PEL in a non-AIDS setting appears to be very rare 
and has been reported in very few cases of solid organ Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
transplant  patients,
50,61,62 and  a  few  cases  have  also 
been described in HIV negative elderly men, most of 
them originating from HHV-8 endemic areas.
63,64 The 
clinical  outcome  of  AIDS-related  and  post-transplant 
PEL is very poor, with a median survival from 2 to 6 
months, despite chemotherapy.
50,52,57 Decreasing CD4+ 
cell counts seem to be the most important indicator of 
progression  of AIDS-related  PEL.
65 In HIV  negative 
patients, PEL may have a more indolent clinical course 
without specific therapy and may initially respond to 
drainage procedures.
63 Recently, it  has been reported 
that azidothymidine and interferon- induce apoptosis 
in  PEL  cells  either  in  vitro  or  in  vivo,
66,67 and  PEL 
remission was observed in a patient on anti-retroviral 
therapy.
68 We have demonstrated that cidofovir at high 
doses induces in vitro apoptosis in PEL cell lines and 
PEL  remission  in  four  HIV  negative,  elderly  Italian 
men treated with intrapleural/intraperitoneal injections 
of  cidofovir,  who  had  recurrent  effusions  not 
responding either to pleural/peritoneal drainages or to 
chemotherapy.
69,70 Recent in vitro data have shown that 
glycyrrhizic acid, contained in the licorice root, induces 
apoptosis  of  PEL  cells,  by  down-regulating  the 
synthesis of the HHV-8 LANA-1.
71 Other approaches 
have  recently  been  considered  for  the  treatment  of 
PEL, based on the targeting of viral gene products,
72,73
providing the basis for new therapeutic options for PEL 
patients  who  are  generally  poor  candidates  for 
aggressive chemotherapy. 
Multicentric Castleman’s  Disease  (MCD) and MCD-
associated plasmablastic lymphoma. MCD of plasma 
cell  type  is  an  atypical  lymphoproliferative  disorder, 
which is histologically characterized by abundance and 
prominent alterations of the germinal centers, marked 
plasmacytic  infiltration,  and  vascular hyperplasia.
74 
Two types of malignancies, lymphoma and KS, have 
been reported to occur during the course of MCD in 
18%  and  13%  of  cases  respectively.
74 HHV-8  DNA 
sequences have been detected in most of MCD cases 
occurring in HIV positive patients, but only in few HIV 
negative cases.
75-78 HHV-8 infection is also found in 
most  MCD  patients  with  associated  POEMS 
(polyneuropathy,  organomegaly,  endocrinopathy,  M 
protein, skin changes) syndrome.
79 One case of HHV-8 
positive  MCD  has  also  been  reported  in  a  renal 
transplant  patient  with  KS.
80 HHV-8  positive  MCD 
cells,  expressing  LANA-1,  morphologically  resemble 
plasmablasts and are localized in the mantle zone of the 
follicles.
81 These  plasmablasts  show   light-chain 
restriction  and  coalesce  to  form  microscopic 
lymphomas in some MCD cases, which could herald 
the  development  of  frank  HHV-8  positive 
plasmablastic  lymphoma.
82-84 A  role  in  the 
pathogenesis of MCD for an over-expression of IL-6, a 
cytokine  which  promotes  B  cell  survival  and 
proliferation, has been proposed.
74 The expression of v-
IL-6 in a proportion of HHV-8 infected MCD cells
85-88
thus appears to support such a pathogenic mechanism. 
This is consistent with findings that exacerbations of 
systemic symptoms in MCD correlate with an increase 
in  HHV-8  viral  load  together  with  IL-6  and  IL-10, 
which  thus  represent  markers  of  disease  activity.
89,90
Recent  studies  suggest  that  HHV-8  positive  MCD 
cases  have  a  more  aggressive  clinical  course  and  a 
poorer prognosis.
82 With regard to therapy, single agent 
chemotherapy  with  vinblastine  is  the  most  effective 
therapeutic  option  and  may  prolong  survival.
91 A 
patient with MCD has successfully been treated with 
retinoic  acid  and  prednisone.
92 Ganciclovir  has  also 
been  effective  in  attenuating  the  constitutional 
symptoms  in  some  cases  of  HIV-associated  HHV-8 
positive  MCD  cases.
93 Recently,  treatment  of  MCD 
with humanized anti-IL-6 receptor antibody has been 
reported  to  be  safe  and  to  alleviate  chronic 
inflammatory symptoms and wasting in a series of 28 
patients, followed-up for 60 weeks.
94
Other diseases. The pathogenetic association between 
HHV-8  infection  and  the  development  of  multiple 
myeloma, proposed by Rettig and colleagues,
95 has not 
been confirmed.
96-98 HHV-8 infection is certainly rare 
in  lymphoproliferative  diseases  other  than  PEL  or 
MCD, both in HIV positive and HIV negative subjects. 
Moreover,  the  occurrence  of  HHV-8  positive  solid 
lymphomas, usually extranodal and extracavitary, but 
with pathobiological features mimicking those of PEL, 
has been described in AIDS as well as in HIV negative 
patients.
99 HHV-8  infection  was  documented  in 
association with hepatitis C virus infection in one case 
of  plasma  cell  leukemia,
100 and  three  HIV  negative 
cases of a germinotropic lymphoproliferative disorder 
characterized  by  plasmablasts  coinfected  by  HHV-8 
and  EBV  have also  been  described.
101 HHV-8 DNA 
and LANA-1 antigens have been detected in liver, lung 
and bone marrow tissues from patients affected with 
common  variable  immunodeficiency  and 
granulomatous/lymphocytic  interstitial  lung  disease, 
suggesting a pathogenetic viral role in this disorder.
102
HHV-8  DNA  was  also  found  in  a  single  case  of 
primary  cerebral  lymphoma,  in  a  woman  who  had 
received  long-term  steroid  therapy  for  uveitis, 
suggesting that HHV-8 infection may be occasionally 
involved  in  a  lymphoproliferation  process  associated 
with iatrogenic immunesuppression.
103 Consistent with 
this,  the  occurrence  of  an  EBV  negative,  HHV-8 
positive,  monoclonal,  lymphoproliferative  disease  of 
polymorphic  type  has  recently  been  reported  in  a 
HHV-8  seronegative  Jewish  man,  nine  months  after 
receiving  a  kidney  from  his  HHV-8  seropositiveMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Main biological, epidemiological and hematologic features of human β-herpesviruses and HHV-8 infections.
Herpes 
Virus
Tropism Epidemiology
Non-neoplastic 
hematologic 
manifestations
Associations with 
neoplastic diseases
HHV-6
Peripheral blood mononuclear 
cells (mainly  T lymphocytes 
and monocytes); hematopoietic 
progenitor cells; neuroglial 
cells; salivary gland epithelial 
cells. Lifelong persistence also 
as chromosomal genome 
integration.
Worldwide diffusion (variants 
A and B, with 90% nucleotide 
identity), infection early in life. 
Transmission: saliva, in utero, 
blood, organ transplant.
Mononucleosis-like 
syndrome, reactive 
lymphadenopathies, 
hemophagocytic syndrome, 
pancytopenias. 
Possible role in Rosai 
Dorfman Disease.
Possible role in 
Angioimmunoblastic T-
cell Lymphoma and in 
Hodgkin’s disease.
HCMV
Hematopoietic progenitor cells 
(mainly monocyte-
macrophages); peripheral blood 
mononuclear cells; endothelial 
cells and fibroblasts.
Worldwide diffusion, 
seropositivity increasing with 
age (98% over 50 years old). 
Transmission: saliva, in utero, 
sexual route, blood, organ 
transplant.
Mononucleosis-like 
syndrome, hemophagocytic 
syndrome, pancytopenias.
Possible role in Large 
Granular Lymphocyte 
lymphocytosis.
HHV-8
B-lymphocytes; hematopoietic 
progenitors cells; microvascular 
endothelial cells (lymphatic and 
blood vascular cells).
Not ubiquitary diffusion: 
seroprevalence 30-70% in 
endemic African areas, 10-25% 
in Mediterranean areas. 
Transmission: vertical in 
endemic areas, sexual in non-
endemic areas; organ transplant, 
blood?
Reactive 
lymphadenopathies, 
hemophagocytic syndrome, 
pancytopenias, bone 
marrow aplasia in organ 
transplant patients.
Kaposi’s Sarcoma, 
Primary Effusion 
Lymphoma, Multicentric 
Castleman’s 
Disease/plasmablastic 
lymphoma.
father.
104 Non  malignant  plasmacytic  proliferations 
have also been reported in two solid organ transplant 
patients
105 as  well  as  in  a  few  Italian  cases  of  HIV 
negative  angioimmunoblastic  lymphadenopathy.
106
Interestingly, a few cases of benign lymphadenopathy 
with  germinal  center  hyperplasia  and  increased 
vascularity  in  which  HHV-8  DNA  sequences  were 
detected, have been reported in HIV negative
75,106 and 
HIV positive
106,107 young adults. The only one case of
well  documented  HHV-8  primary  infection  in  HIV 
positive  subjects  has  been  reported  to  be  associated 
with  the  development  of  fever,  splenomegaly  and  a 
cervical  lymphadenopathy,  characterized  by 
angiolymphoid  hyperplasia.
108 Thus,  the  above 
mentioned  histologic  features  of  florid  follicular 
hyperplasia  and  increased  vascularity,  which  are 
observed  also  in  MCD,  are  likely  to  represent  the 
distinct  histologic  pattern  of  lymphoid  response 
induced  by  HHV-8.  Interestingly,  a 
lymphoproliferative disease characterized by persistent 
angiofollicular lymphadenopathy is induced in simian 
immunodeficiency-virus  infected  Rhesus  Macaques, 
following  infection  with  the  simian  homologue  of 
HHV-8.
109
It  is  also  likely  that,  as  with  other  human 
herpesviruses,  a  HHV-8  primary  infection  or 
reactivation,  is  manifested  by  non  neoplastic 
pathological  changes.  Thus,  HHV-8  DNA  has  been 
detected in the pathologic lung tissue of HIV negative 
and positive patients with interstitial pneumonitis.
110,111
Fever,  cutaneous  rash  and  hepatitis  have  also  been 
reported in an Italian patient with NHL, who received 
autologous  peripheral  blood  stem  cell  (PBSC) 
transplantation  and  showed  HHV-8  reactivation.
112
Recently, we had also the possibility to study primary 
HHV-8  infection  in  two  patients  four  months  after 
kidney  transplantation  from  the  same  HHV-8-
seropositive  cadaveric  donor.  Seroconversion  and 
viremia coincided with development of a disseminated 
KS in one patient and with an acute syndrome of fever, 
splenomegaly,  cytopenia,  and  marrow  failure with 
plasmacytosis in the other patient.
113 We also reported 
a further case of HHV-8 reactivation associated with 
fever  and  marrow  aplasia  with  plasmacytosis  in  a 
patient  with  NHL,  after  autologous  PBSC 
transplantation.  HHV-8  transcripts  and  latency 
associated  nuclear  antigen  were  expressed  in  the 
immature myeloid progenitors of the aplastic marrow 
of  these  patients.
113 In  recent  studies  we  and  others 
have  observed  that  HHV-8  may  also  exert  a 
myelosuppressive effect in vitro,
114,115 suggesting that 
HHV-8  could  also  be  implicated  in  the  complex 
pathophysiology of cytopenias often occurring in HIV 
infected patients.
116 (Table 1)
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